Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis
Authors' conclusion
Empagliflozin exerts a consistent benefit on cardiovascular outcomes and renal function decline, irrespective of baseline insulin use, and reduces the need for sustained insulin initiation in patients with HF and diabetes.
Study context
- Population
- Patients with heart failure (HF) and diabetes in EMPEROR-Reduced and EMPEROR-Preserved, with or without baseline insulin1,333 using insulin
- Participants
- 4,794 patients
- Comparison
- Empagliflozin vs placebo, by baseline insulin use
- Outcome
- Composite of:
- First hospitalization for HF
- Cardiovascular death
Methodological detailspooled patient-level data, subgroup analysis stratified by baseline insulin use
- Pooled patient-level data
- Subgroup analysis stratified by baseline insulin use
Pooled result
As reported in the abstract
First HF hospitalization or cardiovascular death, by baseline insulin use
Empagliflozin vs PlaceboHazard ratio (95% CI)P value
No insulin
0.74(0.63–0.86)
Using insulin
0.81(0.66–1.00)
P = 0.49for interactionFurther pooled results
| Outcome | Empagliflozin | Placebo | OR (95% CI) | |
|---|---|---|---|---|
| Insulin initiation in patients not using insulin at baseline · throughout follow-up | 2.6% | 3.8% | 0.66 (0.50–0.88) | |
| 0.512Odds ratio (log scale) |
Rate of eGFR decline, by baseline insulin use
- Effect consistent irrespective of insulin use
- P for interaction = 0.75
Composite renal outcome, by baseline insulin use
- No effect of empagliflozin in patients using or not using insulin
- P for interaction = 0.30
Original publication
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis. Diabetes Obes Metab. Published 1 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →